6 recruiting, 3 unknown, 2 completed, 1 terminated. 3 Not applicable, 3 Phase 2, 1 Early Phase 1, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Unknown 3 |
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow HLH: new trials by email Literature Review of HLH trials Research Report on HLH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| Gut Health in Children With Cancer Enteral nutrition Food Derived Ingredient - AML (Acute Myelogenous Leukemia, HLH | Recruiting | Great Ormond Street Hospital for Children NHS Foundation Trust | 40 | 2025-01-30 | 2025-03-28 | |
| Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis Adult Refractory Secondary Hemophagocytic Lymphohistiocytosis, Secondary Hemophagocytic Lymphohistiocytosis | Completed | Fudan University | 22 | 2024-05-21 | 2026-04-15 | |
| Establishing a National Egyptian HLH Registry (NEHR) HLH, Hemophagocytic Lymphohistiocytoses | Recruiting | Ain Shams University | 100 | 2024-03-02 | 2026-09-02 | |
| Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen Teniposide - HLH | Not applicable | Unknown | Beijing Friendship Hospital | 20 | 2023-10-22 | 2023-11-02 |
| Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome Tadekinig alfa (IL-18BP) - CRS - Cytokine Release Syndrome, HLH | Early Phase 1 | Recruiting | University of Pennsylvania | 10 | 2022-04-17 | 2026-03-03 |
| Zanubrutinib for HLH Zanubrutinib - HLH | Phase 3 | Completed | Beijing Friendship Hospital | 16 | 2022-02-01 | 2024-04-11 |
| Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement Thiotepa - HLH | Not applicable | Unknown | Beijing Friendship Hospital | 20 | 2022-01-01 | 2023-05-11 |
| Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV low-dose CD20 monoclonal antibody injection - PTLD, CAEBV | Not applicable | Unknown | Beijing Friendship Hospital | 20 | 2021-06-01 | 2022-02-28 |
| Prospective Validation of the OHI Index HLH, Hemophagocytic Lymphohistiocytoses | Recruiting | Meir Medical Center | 300 | 2021-03-03 | 2025-05-13 | |
| Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis 68GaNOTA-Anti-MMR-VHH2 - Solid Malignancy Located in the Head and Neck, Cancer | Phase 2 | Terminated | Universitair Ziekenhuis Brussel | 29 | 2021-01-26 | 2026-06-01 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Clofarabine, Fludarabine, Busulfan - AML, ALL | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2020-11-20 | 2026-03-13 |
Lymphoma, Non-Hodgkin (3) · Anemia, Refractory, with Excess of Blasts (2) · Bone Marrow Failure Disorders (2) · Hemoglobinopathies (2) · Leukemia, Myeloid, Acute (2) · Lymphohistiocytosis, Hemophagocytic (2) · Burkitt Lymphoma (1) · Carotid Stenosis (1) · Congenital Bone Marrow Failure Syndromes (1) · Cytokine Release Syndrome (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1) · Metabolism, Inborn Errors (1)
Hemic and Lymphatic Diseases (6) · Lymphatic Diseases (6) · Hematologic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Anemia (2) · Anemia, Refractory (2) · Bone Marrow Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Histiocytosis (2)
Busulfan (1) · Clinical Trials, Phase I as Topic (1) · Clofarabine (1) · Cyclosporins (1) · Mycophenolic Acid (1) · Teniposide (1) · Thiotepa (1) · fludarabine (1) · fludarabine phosphate (1) · interleukin-18 binding protein (1) · zanubrutinib (1)
Beijing Friendship Hospital (4) · Ain Shams University (1) · Children's Hospital of Philadelphia (1) · Fudan University (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Meir Medical Center (1) · Memorial Sloan Kettering Cancer Center (1) · Universitair Ziekenhuis Brussel (1) · University of Pennsylvania (1)
China (5) · United States (3) · Belgium (1) · Egypt (1) · Israel (1) · United Kingdom (1)
Adi Zoref-Lorenz (1) · Maria Cancio, MD (1) · Timothy Olson, MD, PhD (1) · Tony Lahoutte, MD (1) · Yan Cui (1) · Zhao Wang (1)